A Clinical Trial to study the benefit of the drug Prostaglandin E1 (a vessel that basically dilates the blood vessels) in patients who undergo Living Donor Liver Transplantation

Role of Perioperative Prostaglandin E1 infusion in patients undergoing living donor liver transplantation : a Double blind Randomised trial

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/09/003991

Enrollment

Registered

2013-09-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with acute or chronic liver failure undergoing liver transplantation

Interventions

Intervention1: Prostaglandin: Alprostadil 500mcg diluted in 50ml normal saline and given as infusion @ 0.025 ml/kg/hr. Infusion to be continued for a total of 96 hours Control Intervention1: Normal sa

Eligibility

Inclusion criteria

Inclusion criteria: All patients undergoing live Donor liver transplantation

Exclusion criteria

Exclusion criteria: ABO incompatible liver transplantation

Design outcomes

Primary

Measure	Time frame
Initial poor graft functionTimepoint: Post transplant day 5	—

Secondary

Measure	Time frame
Hepatic artery thrombosis / portal vein thrombosisTimepoint: 30 days;Length of ICU stayTimepoint: 30 days;MortalityTimepoint: 30 days;Peak SGOT and SGPT levelsTimepoint: 7 days;Postoperative bile leakTimepoint: 30 days;Postoperative bleedingTimepoint: 30 days;Primary graft non functionTimepoint: 30 days;Prothrombin time / INR peak and meanTimepoint: 14 days;Serum bilirubin peak and mean levelTimepoint: 14 days;Serum creatinine Peak / meanTimepoint: 14 days	—

Measure

Time frame

Hepatic artery thrombosis / portal vein thrombosisTimepoint: 30 days;Length of ICU stayTimepoint: 30 days;MortalityTimepoint: 30 days;Peak SGOT and SGPT levelsTimepoint: 7 days;Postoperative bile leakTimepoint: 30 days;Postoperative bleedingTimepoint: 30 days;Primary graft non functionTimepoint: 30 days;Prothrombin time / INR peak and meanTimepoint: 14 days;Serum bilirubin peak and mean levelTimepoint: 14 days;Serum creatinine Peak / meanTimepoint: 14 days

—

Countries

India

Contacts

Public ContactViju Kumar Bharathan

Amrita Institute of Medical Sciences, Kochi

sudhi@aims.amrita.edu9388623851

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026